Ball (NYSE: BALL) recently received a number of ratings updates from brokerages and research firms:
- 11/4/2024 – Ball had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $75.00 price target on the stock.
- 11/4/2024 – Ball had its price target lowered by analysts at Mizuho from $69.00 to $67.00. They now have a “neutral” rating on the stock.
- 11/1/2024 – Ball had its price target lowered by analysts at Wells Fargo & Company from $63.00 to $61.00. They now have an “equal weight” rating on the stock.
- 10/17/2024 – Ball had its price target lowered by analysts at Royal Bank of Canada from $77.00 to $75.00. They now have an “outperform” rating on the stock.
- 10/15/2024 – Ball had its price target raised by analysts at Wells Fargo & Company from $61.00 to $63.00. They now have an “equal weight” rating on the stock.
- 10/2/2024 – Ball had its price target raised by analysts at Citigroup Inc. from $66.00 to $69.00. They now have a “neutral” rating on the stock.
Ball Price Performance
Shares of NYSE BALL traded up $0.52 during trading on Monday, reaching $59.53. The company had a trading volume of 892,585 shares, compared to its average volume of 1,801,276. The company has a current ratio of 1.09, a quick ratio of 0.88 and a debt-to-equity ratio of 0.79. Ball Co. has a twelve month low of $48.05 and a twelve month high of $71.32. The stock has a 50-day moving average price of $65.18 and a two-hundred day moving average price of $65.03. The stock has a market capitalization of $18.07 billion, a PE ratio of 4.49, a price-to-earnings-growth ratio of 1.50 and a beta of 0.90.
Ball (NYSE:BALL – Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.04. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.13 billion. Ball had a net margin of 34.05% and a return on equity of 17.46%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.83 earnings per share. As a group, sell-side analysts predict that Ball Co. will post 3.12 earnings per share for the current year.
Ball Announces Dividend
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Catalyst Capital Advisors LLC purchased a new position in shares of Ball in the 3rd quarter valued at $47,000. Friedenthal Financial acquired a new stake in Ball in the 2nd quarter valued at $47,000. Quarry LP raised its position in Ball by 598.6% in the second quarter. Quarry LP now owns 999 shares of the company’s stock valued at $60,000 after purchasing an additional 856 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Ball by 29.1% during the third quarter. Farther Finance Advisors LLC now owns 1,011 shares of the company’s stock worth $69,000 after purchasing an additional 228 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Ball by 334.0% in the second quarter. EverSource Wealth Advisors LLC now owns 1,059 shares of the company’s stock worth $68,000 after buying an additional 815 shares during the period. Institutional investors and hedge funds own 86.51% of the company’s stock.
Ball Corporation supplies aluminum packaging products for the beverage, personal care, and household products industries in the United States, Brazil, and internationally. The company manufactures and sells aluminum beverage containers to fillers of carbonated soft drinks, beer, energy drinks, and other beverages.
Featured Stories
- Five stocks we like better than Ball
- How to Start Investing in Real Estate
- Intel: Is Now the Time to Be Brave?Â
- Election Stocks: How Elections Affect the Stock Market
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Ball Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ball Co and related companies with MarketBeat.com's FREE daily email newsletter.